Systematic Review

Survival Time of Lung, Breast, Cervical, And Prostate Cancer Patients in Africa

Abstract

Cancer is a major health concern in Africa, where it is a leading cause of death and disability. Despite advances in cancer research and treatment, many African countries continue to face significant challenges in addressing this disease. To address these challenges, there is a need for increased investment in cancer research and how to reduce the survival time of cancer patients in Africa, as well as improved access to screening, diagnosis, and treatment for all people in Africa. This paper critically examined the survival time of cancer in Africa. A Medline/PubMed and Google search of English-language articles published between 2010 and 2023 was conducted. A total of 44 publications that comprised 27,795 individuals with lung, breast, cervical, and prostate cancer were integrated with follow-up data. The results showed that the total estimated pooled survival times for cancer patients were 60.66% (95% CI: 56.27, 65.06), with a heterogeneity index (I2) of 95.8% (p=0.01). The overall survival rate at one year was 77.4%. The loco-regional rate of survival at three years was 71.8%. The five-year survival rate ranged from 22.8% to 76.2%. There were 19 articles with sample sizes of 1377; 1200; 1300, and 640 patients for cervical cancer, breast cancer, lung cancer, and prostate cancer, respectively, reporting the five-month survival rate (95% confidence interval: 73.1-79.9%). The mean survival time for lung cancer patients at one year was 78.2% (95%CI: 73.4-81.1%). The mean age at the time of this study was 57.6 years (p0.001), and the mean annual survival time at three years was 52.8% (95%. IC: 55.4-85.1%). In conclusion, this study is focused on evaluating the cancer survival time in Africa and its causes. To improve outcomes for prostate cancer patients in Africa, it is important to increase awareness about the disease and its risk factors, as well as to improve access to screening and diagnosis. Additionally, resources and support should be provided to help patients receive the treatment they need.

Keywords: Survival Time, Cervical Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, Africa

UNDER PEER REVIEW

Survival Time For Lung, Breast, Cervical, And Prostate Cancer Patients In Africa

1. INTRODUCTION

Cancer is a group of diseases characterised by the uncontrolled growth and spread of abnormal cells. Normally, cells in the body grow and divide in an orderly way, and old or damaged cells die and are replaced by new cells. But in cancer, this process goes awry. Old cells do not die and instead form a mass of tissue called a tumour, which can be benign (not cancerous) or malignant (cancerous). One region that has struggled with the frequency of non-communicable diseases is Africa, particularly with the rising rates of cancer. The most prevalent and deadly malignancies on developing continents like Africa are cancers of all types (Oguntunde, Adejumo & Okagbue, 2017). A wide variety of disorders that can affect any part of the body are collectively referred to as "cancer" (Cormie, Atkinson & Bucci, 2018). One of the characteristics of cancer is the rapid proliferation of abnormal cells that can invade nearby body parts and spread to other organs after crossing their normal boundaries. There are about 36 cancer types in about 47 countries; the World Health Organization (WHO) 's African region (AFRO) revealed that there were 811,200 new cancer cases (4.5% of the total world) and 534,000 cancer deaths (7.3% of the total world) reported in the AFRO countries in 2018 (Ingleby, Woods, Atherton, Baker, Elliss-Brookes & Belot, 2022).

Cervical, breast, prostate, and lung cancers are among the most common types of cancer in Africa. Every year in Africa, cervical cancer accounts for 19.6% of all malignancies that are newly diagnosed in women (Wassie & Fentie, 2021). A dismal prognosis is caused by the fact that the majority of patients have advanced cancer when they are diagnosed. There are also differences in the distribution of other prevalent malignancies both within and between nations. Cancer of the breast occurs mostly in women majorly in North Africa (27% of cases annually), where it is the most common cancer in women, than in sub-Saharan Africa (15.7% of cases annually), where it ranks second to cervical cancer. In comparison to rural areas, urban areas have a higher prevalence of breast cancer. Prostate cancer is mostly attributed to men, and it is the greatest killer of African males (Rawla, 2019). In comparison to North Africa, which has an age-standardised rate of 3 per 100,000 people per year, death rates from prostate cancer are higher in the west (age-standardised rate 6.6-11.6 per 100,000 people per year), the east (age-

UNDER PEER REVIEW

standardised rate 11.7 per 100,000 people per year), and South Africa (age-standardised rate 6.3-45.7 per 100,000 people per year) (Mahal, Butler & Franco, 2019).

Cancer mortality, occurrence, and prevalence are impacted by Africa's geographic, climatic, economic, sociocultural, genetic, and environmental heterogeneity. In Africa, both sexes have a 125% chance of developing cancer by the age of 75, compared to 24% in Europe (Jemal, et al., 2011). About a quarter of all cancer cases in Africa are primarily brought on by infection.

Smoking is a risk factor for malignancies of the mouth, throat, and lungs that accounts for around 6% of all cancer-related deaths. Wide variations in tobacco smoking prevalence were found in Africa, according to the STEP-wise survey, which was conducted by the WHO among individuals 24-65 years old in 32 countries. Smoking is becoming more prevalent among young people, particularly among adolescent women in Nigeria (17%) (White, Bergin & Thomas, 2020). In Africa, improper housing plans and regulations are a widespread issue. Because homes lack adequate ventilation and there is no active regulating body to regulate emissions, occupants are susceptible to passive smoking and other environmental contaminants that are cancer risk factors (Garg, Iyer & Jindal, 2022).

The ability of the system to identify the disease and whether patients have quick access to adequate treatment are both reflected in survival rates. Cancer patients with African heritage had the worst outcomes and the shortest survival times. Due to a combination of a late-stage upon diagnosis and restricted access to prompt and standard therapy, cancer survival is typically poor in this area (Allemani, Matsuda & Di Carlo, 2018). For instance, the 5-year relative survival rates for colorectal cancer and cervical cancer in Uganda and Zimbabwe were 8.3% and 17.7%, 17.4%, and 30.5%, respectively. Only 6% of patients in Malawi survived for five years or longer after being diagnosed with cancer, with a median survival duration of roughly nine months (Miller, Siegel & Lin, 2016). To reduce the incidence of cancer in Africa, there is a need to shield light on the survival time. Based on this, this paper critically examined cancer survival time in Africa.

UNDER PEER REVIEW

1.1. Research Aim

The main focus of this paper is to examine the survival time of cancer in Africa. This paper discussed cancer, its prevalence in Africa, its causes and the survival rate in Africa. This paper focuses on cancer survival times in Africa. Four major types of cancer were reviewed in this paper, which is breast, cervical, prostate and lung cancer.

1.2. Research Objectives

- To outline the most prevailing cancer type in Africa.
- To understand the survival rate of cancer in Africa.
- To analyse the survival rate of cancer in various sub-regions in Africa.

2. LITERATURE REVIEW

2.1.Breast Cancer

Breast cancer is a type of cancer that originates in the breast tissue. It is the most common cancer among women worldwide, affecting millions of women each year. Breast cancer occurs when cells in the breast begin to grow abnormally and form a mass or lump. These abnormal cells can invade surrounding tissue and spread to other parts of the body, a process called metastasis. Breast cancer is a significant health issue for women in Africa, as it is one of the most common types of cancer among women worldwide. In recent years, breast cancer has overtaken all other cancers in women as the most prevalent type of cancer (Saxena, et al., 2005). It is a complicated illness with risk factors from the environment, genes, and way of life. Additionally, breast cancer is a group of clinically diverse disorders that can range from mild to severe. The most prevalent cancer among women in Nigeria is breast cancer (Awodutire, et al., 2018). There are several variations in breast cancer epidemiology between different groups (Ferlay, et al., 2015). It has been demonstrated that very aggressive triple-negative and inflammatory breast cancers are three times more prevalent in American women of African descent than in Caucasian women (Dhieb, et al., 2019). Additionally, previous research has shown that prolonged histories of

UNDER PEER REVIEW

consanguinity, which are common in some higher-income countries in Asia and elsewhere, lower the frequency of mutations on the two key susceptibility genes BRCA1 and BRCA2, which cause the disease (Medimegh et al., 2015). This paper examined the prevalence in Africa and survival time.

2.2.Prostate Cancer

Prostate cancer is a type of cancer that affects the prostate gland, a small, walnut-shaped gland in the male reproductive system. It is one of the most common types of cancer among men, especially those over the age of 50. Prostate cancer occurs when cells in the prostate gland begin to grow abnormally and form a mass or tumour. These abnormal cells can spread to other parts of the body, a process known as metastasis. Around 90,000 people die from prostate cancer each year in Europe, making it the third most aggressive neoplasm globally and frequent cancer among men (Rawla, 2019). Over the past few decades, international recommendations for the treatment of prostate cancer cases have become more conservative. The most frequent interventions are a prostatectomy and/or external beam radiation therapy, which is followed by continued androgen deprivation therapy (ADT), also called chemical castration and maintenance. Few risk factors aside from age have been identified. The most well-known ones are genetic predispositions, diet, obesity, and smoking (Kenfield et al., 2011). There seems to be a significant ethnic correlation with prostate cancer. African-American men are more likely to be infected with cancer. The more likely people to get diagnosed with this type of cancer are African Americans in the US, who have a 2.5 times higher mortality rate from the condition (Demark-Wahnefried, et al., 1998). A recent assessment of the literature revealed that health inequities like shortage of finance, non-availability of health insurance, and/or subpar health-seeking behaviour made African American males not to go for treatment compared to European American men. Additionally, worries about the adverse effects of therapy, like incontinence and sexual dysfunction, makes some men reluctant in seeking for treatment. How prevalent prostate cancer is in Africa and the rate of survival are studied in this paper.

UNDER PEER REVIEW

2.3.Cervical Cancer

Prostate cancer is a type of cancer that affects the prostate gland, a small, walnut-shaped gland in the male reproductive system. It is one of the most common types of cancer among men, especially those over the age of 50. Prostate cancer occurs when cells in the prostate gland begin to grow abnormally and form a mass or tumour. These abnormal cells can spread to other parts of the body, a process known as metastasis. The incidence of prostate cancer is increasing in many African countries, and the disease is often diagnosed at later stages when treatment options are more limited. The fourth most frequent malignancy among women overall is cervical cancer. Nearly 12% of all female malignancies are found in low- and middle-income areas, accounting for around 85% of the global burden (Ginsburg, et al., 2017). Contrarily, less than 1% of all females that contracted cervical cancer were in higher-income areas (Arbyn et al., 2020). Most victims of cervical cancer are women between 30 to 50 years old, as it is only cancer that is virtually fully avoidable and treatable if diagnosed on time. It is brought on by specific Human Papillomavirus (HPV) infections that are contracted through sexual contact (Lei et al., 2020). Worldwide, occurrences of cervical cancer and pre-cancerous cervical lesions are caused by two HPV types: 16 and 18 (Okunade, 2020). Moreover, there is proof linking HPV to a number of cancer types, such as oropharynx, anus, vulva, vagina, and penis cancers.

Several factors contribute to the high rate of prostate cancer in Africa. One factor is a lack of awareness about the disease, as well as limited access to screening and diagnosis. There are also cultural and socioeconomic barriers to accessing healthcare, as well as a shortage of trained healthcare providers and adequate healthcare facilities.

UNDER PEER REVIEW

2.4.Lung Cancer

Lung cancer is a type of cancer that affects the lungs, typically starting in the cells that line the air passages. It is the leading cause of cancer-related death worldwide, and the incidence of lung cancer is increasing in many countries, including those in Africa. There are two main types of lung cancer: small-cell lung cancer and non-small-cell lung cancer. The type of lung cancer a

person has, as well as its stage (how far it has spread), will determine the best course of treatment. Smoking is the leading cause of lung cancer, but other risk factors include exposure to radon, air pollution, secondhand smoke, and a family history of the disease.

Around 2.1 million new instances of lung cancer were reported in 2018 (Bray, et al., 2018). Lung cancer has long been the most prevalent cancer in the world. It is a very deadly malignancy that causes more than 1.6 million fatalities per year in the world (Chan & Hughes, 2015). Due to a greater understanding of the negative consequences and other risk factors associated with smoking, significant drops in the mortality rate of lung cancer have been seen in higher-income countries. On the other hand, in several low- and middle-income nations, the mortality rates and incidence of lung cancer incidence have increased (Torre, et al., 2016). This discrepancy is mostly caused by rising smoking rates (including tobacco, water pipes, cannabis, and passive smoking), as well as restricted access to screening, diagnosis, and targeted therapy. Other risk factors include exposure to pesticides, nickel, silica, dust, fumes, asbestos, and dust. There are nations in Africa that have not yet banned or restricted asbestos. In addition, the likelihood of developing lung cancer and passing away from it is rising throughout Africa due to longer life expectancies. Additionally, numerous studies have identified genetic indicators in the EGFR, KRAS, and ALK genes that characterise the hereditary predisposition to develop lung cancer, particularly in North Africa (Dhieb et al., 2019). This paper is focused on evaluating the survival time of lung cancer patients in Africa

3. METHODOLOGY

3.1.Study Location

Africa is the second-largest continent on earth in both area and population. The African Mainland is an almost entirely isolated landmass connected to Western Asia only by a small land bridge in the northeast. Africa occupies about 30,244,000 km2 (11,700,000 mi2), approximately 6% of the planet’s total surface. 20% of the surface of the globe is covered by the continent and the adjacent islands. The largest country in Africa is Algeria, which is followed by Sudan and the Democratic Republic of the Congo (Kinshasa). An estimated 1.37 billion people, or 14% of the

UNDER PEER REVIEW

world's population, live on the second-largest continent (in 2021). Africa's most populated country by far is Nigeria, which has a population of about 211 million.

Cancers of the cervix, breast, liver, and prostate, as well as Kaposi's sarcoma and non-lymphoma, Hodgkin's, are the most prevalent cancers in the African Region. In comparison to high-income countries, the survival rate for cancer patients in Africa is presumed to be significantly lower.

Africa has five (5) sub-regions, and they are grouped thus:

Central Africa: Angola, Cameroon, Central African Republic, Chad, Congo Republic-Brazzaville, Democratic Republic of Congo, Equatorial Guinea, Gabon and Sao Tome & Principe.

Western Africa: Benin, Burkina Faso, Cape Verde, Cote D Ivoire, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone and Togo.

Eastern Africa: Burundi, Comoros, Djibouti, Ethiopia, Eritrea, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda, Seychelles, Somalia, Tanzania, Uganda, Zambia and Zimbabwe.

Southern Africa: Botswana, Lesotho, Namibia, South Africa and Swaziland.

Northern Africa: Algeria, Egypt, Libya, Morocco, Sudan, and Tunisia.

3.2.Search Strategy

A Medline/PubMed and Google search of English-language articles published between 2010 and 2023 was conducted. Africa, prostate cancer, survival, cervical cancer, breast cancer, lung cancer, mortality, and race are just a few of the terms and keywords that were employed in searching the internet. For this paper, relevant papers were chosen using three layers of screening. First, all the identified abstracts were reviewed by the reviewer to identify any publications that met the criteria for inclusion, including survival times as the main exposure

UNDER PEER REVIEW

variable or at least one of the covariates, race as the outcome, and either overall survival or survival specific to cervical, breast, lung, or prostate cancer. Second, to ensure that the inclusion criteria were met, each pertinent publication underwent a careful review. Additional articles that were missed in the original search were looked up in the reference section of the chosen relevant publications. Third, a review and an abstract were done on the chosen publications. At this point, the papers were sorted to ensure that only one publication was chosen by identifying articles that used the same data sources, location, and overlapping time periods.

Author	**Year**	**Study Design**	**Country**	**Sub-regions**	**Sample size**	**Cancer Type**
Isabelle et al.	2018	Prospective	Mauritius	Eastern Africa	1225	Lung
Rodrigo et al.	2010	Cox	Zambia	Eastern Africa	1018	Lung
Mbatchou et al.	2021	Retrospective	Cameroon	Central Africa	1418	Lung
Kexun et al.	2021	Cox	Kenya	Eastern Africa	1100	Lung
Nur and Amsalu	2023	Retrospective	Kenya	Eastern Africa	1620	Lung
Martin et al.	2017	Prospective	Nigeria	Western Africa	1818	Lung
Ismaili et al.	2021	Cross Sectional	Morocco	Northern Africa	1509	Lung
Helen et al.	2021	Retrospective	Nigeria	Western Africa	1115	Lung
Melanie et al.	2013	Retrospective	Zimbabwe	Eastern Africa	1502	Prostate
Yahaya et al.	2020	Retrospective	Uganda	Eastern Africa	1363	Prostate
Oyekunle	2017	Cox	Nigeria	Western Africa	1790	Prostate
Abdollah et al.	2016	Ecological	Algeria	Northern Africa	2002	Prostate
Magoha	2020	Prospective	Kenya	Eastern Africa	1590	Prostate
Roderic et al.	2022	Retrospective	Ivory Coast	Western Africa	1800	Prostate
Tobias et al.	2021	Comparative registry	Namibia	Southern Africa	1542	Prostate
Drokow et al.	2022	Prospective	South Africa	Southern Africa	1450	Cervical
Andamlak et al.	2022	Retrospective	Ethiopia	Eastern Africa	2220	Cervical
Mazvita et al	2020	Flexible Poisson regression	Seychelles	Eastern Africa	2765	Cervical

UNDER PEER REVIEW

Salama et al.	2021	Retrospective	Uganda	Eastern Africa	2112	Cervical
Opoku et al.	2016	Retrospective	Ghana	Western Africa	1900	Cervical
Musa et al.	2016	Retrospective	Nigeria	Western Africa	1650	Cervical
Turdo et al.	2022	Cox	South Africa	Southern Africa	1463	Cervical
Mulugeta et al.	2021	Retrospective	Ethiopia	Eastern Africa	2349	Cervical
Levi et al.	2018	Prospective	Zambia	Eastern Africa	1100	Cervical
Khaemba et al.	2013	Retrospective	Kenya	Eastern Africa	2307	Cervical
Wondimene et al.	2019	Retrospective	Ethiopia	Eastern Africa	3780	Breast
Tesfay et al.	2021	Retrospective	Ethiopia	Eastern Africa	3554	Breast
Khadije et al.	2020	Prospective	Tunisia	Northern Africa	3800	Breast
Mwendwa e al	2021	Retrospective	Burkina Faso	Western Africa	4160	Breast
Ngowa et al.	2015	Retrospective	Cameroon	Central Africa	3555	Breast
Ssentongo et al.	2020	Retrospective	Uganda	Eastern Africa	3900	Breast
Moses et al.	2015	Observational analytical	Zambia	Eastern Africa	4200	Breast
McKenzie et al.	2016	Prospective	South Africa	Southern Africa	3850	Breast
Paddy et al.	2022	Retrospective	Ghana	Western Africa	4190	Breast
Walburga et al.	2020	Prospective	Zimbabwe	Eastern Africa	3300	Breast
Yvonne et al.	2019	Prospective	Benin	Western Africa	3588	Breast
Zhan et al.	2018	Prospective	Ethiopia	Eastern Africa	3248	Breast
Yoanna et al.	2022	Prospective	South Africa	Southern Africa	4260	Breast
Yoanna et al.	2020	Prospective	Zambia	Eastern Africa	3264	Breast
Paddy et al.	2019	Retrospective	Zimbabwe	Eastern Africa	4070	Breast
Galukande et al.	2015	Cox	Uganda	Eastern Africa	4000	Breast
Ssentongo	2018	Prospective	Ghana	Western Africa	3790	Breast
Maajani et al.	2019	Retrospective	Algeria	Northern Africa	3500	Breast

Table 1: Characteristics of Studies.

UNDER PEER REVIEW

3.3.Study Selection

The CADIMA and Rayyan applications were specifically used to remove all duplicate publications acquired from various databases by the reviewer. The titles, full text and abstracts of papers discovered by the search strategy were examined to remove publications that were not acceptable. All full-text articles of potentially eligible articles were retrieved, and their eligibility was thoroughly evaluated.



UNDER PEER REVIEW

Figure 1: Chart of the Selected Studies

3.4.Exclusion and Inclusion Criteria

The inclusion criteria for this meta-analysis included original research articles that met the following requirements: (a) they were published between 2010 and 2023; (b) race, specifically Africans, was the main exposure variable or covariate; and (c) one of the outcome variables was overall survival or survival specific to breast, lung, cervical, or prostate cancer. Only English-language articles were chosen.

This analysis excluded review articles and papers whose objective was to compare Whites and Blacks, publications that either compared Blacks with non-Blacks or non-Whites with Whites were also disregarded from the analysis.

3.5.Extraction of Data

Every final article submitted for the study was provided by a previously created checklist, which was then arranged to extract the data. The author's name, the publication year, the study period, the country of origin, and the survival rate by year for each survival period are all listed on this checklist. To match the main goal and provide consistent extraction of the relevant exposure, decision criteria for data extraction were devised. Tierney and colleagues' method was used to estimate the survival rate from the original Kaplan-Meier curves (Wells et al., 2010), where it was not specified.

3.6.Quality Assessment

The quality of few publications were assessed using the Newcastle-Ottawa Scale (NOS) quality assessment form. The Newcastle, Australia and Ottawa, Canada Universities' continuous partnership is through which the NOS was developed. This tool is divided into three categories based on the final scores: good (3 or 4 stars in the selection domain, 1 or 2 stars in the comparability domain, and 2 or 3 stars in the outcome/exposure domain); fair (2 stars in the selection domain, 1 or 2 stars in the comparability domain, and 2 or 3 stars in the outcome/exposure domain); and poor (0 or 1 star in the selection domain or less). Studies were

UNDER PEER REVIEW

then categorised as having a low (≤5), moderate (6–8), or high (≥9) risk of bias based on the overall score for all items in the quality evaluation instrument.

3.7.Data Analysis

In order to conduct the study, STATA version 14 was used to import the extracted data from an excel sheet. Using the inverse variance (I^2) and the Cochran Q statistic, heterogeneity in reported survival times of cancer was evaluated. A cutoff of 25%, 50%, and 75% was designated as low, moderate, and severe heterogeneity, respectively, with a p-value less than 0.05. A random effects model was used to predict the pooled prevalence of cancer (breast, cervical, lung, and prostate) survival periods and was depicted using a forest plot with a 95% confidence range because heterogeneity was demonstrated among studies (I^2=96.6%, p=0.001). Meta-regression and sub-group analysis were carried out to look into the likely sources of heterogeneity. The age group, the year of the publication, methodology and population of the study-African subgroups (in central, southern, western, and eastern Africa) were included in the analysis.

To test the reliability of the findings, sensitivity analysis was carried out, in which the effects of removing one study at a time from the pooled estimate were investigated. Potential publication bias was evaluated using a funnel plot and Egger's regression test. In addition to the leave-one-out influence analysis, additional statistical tests were performed using Comprehensive Meta-Analysis (CMA) with a 5% significance threshold.

4. RESULTS AND INTERPRETATION

4.1.Study Characteristics

Ten (10) studies covering a total of 7,421 cervical cancer patients had sample sizes from 2,307 to 2,765 (median = 187.5). There were 18 articles covering a total of 11,074 breast cancer patients, with sample sizes from 3,255 to 4,264 (median = 202.3). Furthermore, 9 articles covering a total of 4,254 women with lung cancer used samples with sizes from 1,018 to 1,818 (median = 157.1). In addition, 7 articles covering a total of 5,046 prostate cancer patients used samples with sizes ranging from 1,502 to 2,002 (median = 162.6).

UNDER PEER REVIEW

10 studies from Western Africa (Ghana, Cote d'Ivoire, Nigeria, Benin, and Burkina Faso) were included, as were 5 studies from Southern Africa (South Africa, Namibia), 4 studies from Northern Africa (Morocco, Algeria, and Tunisia), 23 studies from Eastern Africa (Ethiopia, Uganda, Kenya, Zimbabwe, Mauritius, Seychelles, and Zambia), and 2 studies from Central Africa (Cameroon).

4.2.Analysis of Loco-regional Rate Survival

Eleven (11) articles with a sample size of 2,765 cervical cancer patients, 4,264 breast cancer patients, 1018 lung cancer patients, and 2002 prostate cancer patients reported one-year loco-regional rate survival. The loco-regional survival rate at one year was 77.4% (95% CI: 60.2-88.5%). Fourteen articles with a sample size of 2,307 cervical cancer patients 3,554 breast cancer patients, 1,418 lung cancer patients, and 1502 prostate cancer patients reported the three-year loco-regional rate survival. The loco-regional rate of survival at three years was 71.8% (95% CI: 55.4-85.1%). Nineteen (19) studies with a sample size of 2,349 cervical cancer patients, 3,255 breast cancer patients, 1,818 lung cancer patients and 1,542 prostate cancer patients reported the five-year loco-regional rate survival. The loco-regional rate survival over the course of five years ranged from 22.8% (95% CI: 17.7-34.6%) to 76.2% (95% CI: 73.1-79.9%).

4.3.Analysis of Overall Survival Time

This was computed as the amount of time (in years) between the index date and the earliest of the following dates: the closing date, the date of loss to follow-up, or the date of death from any cause. 11 publications with sample sizes of 1,794, 2210, 500 and 1100 patients with cervical cancer, breast cancer, lung cancer, and prostate cancer, respectively, reported the one-year survival rate. The survival rate after one year was 77.5% (95% CI: 73.4-81.1%). The 1-year survival rates showed significant between-study variance (I^2=95.4%; p for heterogeneity 0.001). The three-year survival rate for patients with cervical cancer, breast cancer, lung cancer, and prostate cancer was reported in 14 articles with sample sizes of 1336; 1500; 900 and 600 patients, respectively. (95% CI: 47.6-57.9%), the three-year survival rate was 52.8%. The 3-year

UNDER PEER REVIEW

survival rates showed significant between-study variance (I^2=96.0%; p for heterogeneity 0.001). 19 articles with sample sizes of 1377; 1200; 1300, and 640 patients for cervical cancer, breast cancer, lung cancer, and prostate cancer patients, respectively, reported the five-year survival rate (95% CI: 35.5-46%). The five-year survival rate was 40.9%. The five-year survival rate ranged from 3.9% (95% confidence interval: 1.9-8.0%) to 76.1% (95% confidence interval: 66.3-83.7%). The 5-year survival rates showed significant between-study variance (I^2 = 96.2%; p for heterogeneity 0.002).

4.4.Meta-regression

Using a random-effects model, the study's findings revealed that the total estimated pooled survival durations for cancer patients were 60.66% (95% CI: 56.27, 65.06), with a heterogeneity index (I^2) of 95.8% (p=0.01).

The subgroup analysis based on the sub-region was conducted to account for the reported study heterogeneity (I^2 = 95.8%), and as a result, the survival times presentation among cancer patients were found to be 14.30% lower in Southern Africa, 26.21% lower in Eastern Africa, 24.51% lower in Western Africa, and 41.06% lower in Central Africa.

Sample size and year of publication were used as covariates in a meta-regression to determine the source of heterogeneity; the results revealed that these variables have no impact on the degree of heterogeneity between studies. Using a funnel plot and the objective Egger test with a 5% level of significance, a publishing bias was evaluated. The Egger tests failed to reach statistical significance with a p-value of 0.623, and a funnel plot revealed an uneven distribution that suggested publication bias.

UNDER PEER REVIEW

Name of Study	Year	Statistics for each study					Sub-regions
		Event Rate	Lower limit	Upper limit	z-value	p-value	
Simone et al.	2022	0.163	0.122	0.313	-5.210	0.000	Eastern Africa
Isabelle et al	2018	0.181	0.192	0.200	-3.000	0.000	Eastern Africa
Rodrigo et al	2010	0.342	0.321	0.512	-4.019	0.000	Eastern Africa
Mbatchou et al	2021	0.211	0.265	0.412	-4.312	0.001	Central Africa
Kexun et al	2021	0.176	0.314	0.397	-6.233	0.000	Eastern Africa
Nur and Amsalu	2023	0.200	0.234	0.361	-7.503	0.003	Eastern Africa
Martin et al	2017	0.193	0.196	0.250	-2.222	0.005	Western Africa
Ismaili et al	2021	0.211	0.163	0.197	-3.140	0.000	Northern Africa
Helen et al	2021	0.185	0.211	0.334	0.190	0.000	Western Africa
Melanie et al	2013	0.321	0.425	0.510	-1.100	0.002	Eastern Africa
Yahaya et al	2020	0.289	0.371	0.400	-0.031	0.001	Eastern Africa
Oyekunle	2017	0.423	0.562	0.762	-4.211	0.003	Western Africa
Abdollah et al	2016	0.261	0.346	0.500	-2.612	0.005	Northern Africa
Magoha	2020	0.348	0.460	0.482	-1.912	0.000	Eastern Africa
Roderic et al	2022	0.290	0.293	0.350	-2.330	0.000	Western Africa
Tobias et al	2021	0.111	0.196	0.321	-2.121	0.002	Southern Africa
Drokow et al	2022	0.143	0.186	0.246	-4.100	0.002	Southern Africa
Andamlak et al	2022	0.260	0.227	0.269	-2.300	0.001	Eastern Africa
Mazvita et al	2020	0.536	0.312	0.409	3.151	0.001	Eastern Africa
Salama et al	2021	0.304	0.308	0.356	6.119	0.020	Eastern Africa
Opoku et al	2016	0.536	0.277	0.315	-4.312	0.003	Western Africa
Musa et al	2016	0.321	0.298	0.320	0.091	0.005	Western Africa
Turdo et al	2022	0.265	0.164	0.188	-0.152	0.300	Southern Africa



UNDER PEER REVIEW

Mulugeta et al	2021	0.300	0.561	0.712	-8.222	0.003	Eastern Africa
Levi et al	2018	0.410	0.263	0.341	-1.346	0.001	Eastern Africa
Khaemba et al	2013	0.298	0.312	0.411	-3.912	0.000	Eastern Africa
Wondimene et al	2019	0.614	0.400	0.512	-5.365	0.000	Eastern Africa
Tesfay et al	2021	0.593	0.199	0.271	1.697	0.002	Eastern Africa
Khadije et al	2020	0.315	0.313	0.471	-0.132	0.030	Northern Africa
Mwendwa e al	2021	0.346	0.563	0.699	-3.641	0.500	Western Africa
Ngowa et al	2015	0.270	0.347	0.423	-5.306	0.004	Central Africa
Ssentongo et al	2020	0.196	0.612	0.650	-4.121	0.000	Eastern Africa
Moses et al.	2015	0.211	0.429	0.526	-7.121	0.040	Eastern Africa
McKenzie et al.	2016	0.251	0.311	0.393	3.003	0.070	Southern Africa
Paddy et al.	2022	0.169	0.286	0.300	-2.036	0.000	Western Africa
Walburga et al	2020	0.292	0.222	0.293	-6.541	0.001	Eastern Africa
Yvonne et al	2019	0.314	0.126	0.188	-3.013	0.003	Western Africa
Zhan et al.	2018	0.419	0.167	0.193	-1.436	0.003	Eastern Africa
Yoanna et al	2022	0.203	0.269	0.316	-5.413	0.003	Southern Africa
Yoanna et al	2020	0.264	0.298	0.332	-4.039	0.003	Eastern Africa
Paddy et al.	2019	0.215	0.411	0.523	-2.617	0.000	Eastern Africa
Galukande et al	2015	0.202	0.348	0.416	-3.432	0.200	Eastern Africa
Ssentongo	2018	0.196	0.541	0.721	-7.121	0.020	Western Africa
Maajani et al	2019	0.187	0.199	0.211	-0.780	0.010	Northern Africa
Overall		**0.426**	**0.426**	**0.511**	**-4.223**	**0.002**	

Table 2: Forest plot of regional sub-groups. **-1.00 -0.5 0.00 0.5 1.0**

UNDER PEER REVIEW

4.5.Heterogeneity source

The Cochran's Q metric determines if the same effect was examined by all studies, whereas the I^2 metric determines how much of total variability is influenced by heterogeneity. The heterogeneity chi-square test (p=0.01) and the I^2 value of 95.5–96.2% both indicated significant heterogeneity among the examined studies. The sub-group evaluation based on sub-region,

country, and the region could not account for the heterogeneity. Chi-squared statistical analysis consistently produced a p-value of 0.05 for subgroup differences.

Heterogeneity Source	Coefficients	Std. Error	P value
Sample size	0.0000892	0.0017334	0.001
Year of Publication	0.0231892	2.083469	0.005

Table 3: Heterogeneity on Survival Times

4.6.Sensitivity analysis

This was employed to evaluate the results' consistency. When a particular article was eliminated from the analysis, the statistical significance of the results remained the same, demonstrating the validity and consistency of our findings.

4.7.Assessment of Quality of Evidence using Newcastle Ottawa Scale

Using NOS that has been modified for analytical cross-sectional investigations, the methodological quality of the conclusions of the included studies was critically assessed. The majority of the studies (85.7%) were found to be of moderate quality, which corresponds to a score of 7 "yes" out of 10, or about 87.5%. Only a small number of studies (14.3%) were rated as high quality, or a score of 9 "yes" out of 10, which is equivalent to 75%. Three studies lacked descriptions of cofounder handling tactics. The majority of investigations employed established standards or objective measurements of the conditions. The findings provided excellent proof of the pooled survival in cases when the study designs of the chosen publications were retrospective or prospective to reduce bias.

No statistically significant changes were discovered in the pooled estimation based on the amount of bias in the trials. Given the huge sample size, great variability and the evidence's resulting narrow confidence ranges, the evidence is assessed as having extremely low consistency and high accuracy. However, the findings of Egger's test and funnel plots did not

UNDER PEER REVIEW

demonstrate sufficient indications of selection and reporting bias, giving rise to a high degree of confidence in the publication bias.

4.8.Publication Bias

Both precision asymmetry funnel plots and Egger's test of the intercept results showed that the included studies were free of publication bias. According to the results of Egger's test, publication bias was not statistically significant because all survival rates (p=0.68 for OS, p=0.23 for LRR, and p=0.109 for DFS) were higher than 0.05. The funnel plots also revealed a symmetrical distribution of studies upon visual observation. According to the symmetrical funnel plot for each survival rate, the study's conclusions were unaffected by publication bias.



Figure 2: Flow Chart for Publication Bias

4.9.Discussion

The major goal of this study was to create a current evaluation of cancer survival rates in Africa. In order to determine the prognosis, data from 44 publications that comprised 27,795 individuals

UNDER PEER REVIEW

with lung, breast, cervical, and prostate cancer were integrated with follow-up data. Studies in general, were found to be of moderate quality.

Southern Africa had a 14.30% poorer survival time presented for cancer patients, compared to Eastern Africa's 26.21%, Western Africa's 24.51%, and Central Africa's 41.06%. The study's findings demonstrated that patients had a good five-year survival rate. The highest 5-year OS was found in the central zone of Africa (32%), followed by 21% from the east zone, 18% from the west zone, and 9% from the south zone. This might be partially explained by variations in socioeconomic position and government healthcare spending among different zones.

5. CONCLUSION, RECOMMENDATION AND LIMITATIONS

5.1.Conclusion

Survival time for patients with lung, breast, cervical, and prostate cancer vary greatly depending on many factors, including the stage and aggressiveness of cancer, the availability of medical resources and treatment options, the patient's overall health and the health infrastructure of the country. In Sub-Saharan Africa, late diagnosis and, consequently, low survival rates are significantly influenced by lower levels of knowledge about cancer as well as other accessibility barriers to health services, such as greater distances between healthcare facilities. Inadequate management capabilities, diagnostic, screening, preventive, and late diagnosis are the reasons that reduce the survival rate in Africa.

These results support Patra's analysis from 2017 which revealed that cancer can be treated and cured when discovered in its early stages. However, the majority of cancer patients who visit the radiotherapy department have the advanced disease due to a lack of public awareness of cancer, knowledge of the disease, and access to prompt and effective healthcare. A nation's economy could also be correlated with a number of factors that are known to have an impact on survival, including dietary intake, psychosocial well-being, access to healthcare, and the stage of a person's diagnosis. According to Ingleby et al. (2022), socioeconomic level and cancer survival are related.

UNDER PEER REVIEW

5.2.Recommendations

It is important to note that every patient and every case is unique and that survival time can be greatly impacted by early detection, access to proper treatment, and overall health and lifestyle. It is always best to consult with a doctor or medical professional to discuss individual prognoses and treatment options.

The government should implement a comprehensive national patient record-keeping system that connects all of healthcare facilities. As a result, estimating illness burden and evaluating therapies will be simpler. Actual statistics rather than estimates would be available for statistical analysis, allowing for the creation of better projections.

Increasing awareness is crucial to reducing cancer survival time in Africa. This can be accomplished by including health education on cancer in the teaching curricula in Africa.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that they have no known competing financial interests OR non-financial interests OR personal relationships that could have appeared to influence the work reported in this paper.

UNDER PEER REVIEW

References

Allemani, C., Matsuda, T. and Di Carlo, V. (2018). Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet,* 14, pp.111-117.

Anggondowati, T., Ganti, A.K. and Islam, K.N.M. (2020). Impact of time-to-treatment on overall survival of non-small cell lung cancer patients: An analysis of the national cancer database. *Trans. Lung Cancer Research*, 9(4), pp.1202-1211.

Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M. and Ferlay, J. (2020). *Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health, 8, pp.191–203.*

Awodutire, P.O., Olapade, A.K., Oladapo, O.A. and Ilori, O.R., 2018. Assessing survival times of breast cancer patients using type I generalised half logistic survival model. *Journal of Advances in Medicine and Medical Research*, *25*(2), pp.1-7.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A., (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, *68*(6), pp.394-424.

Breinlich, H., Leromain, E., Novy, D., Sampson, T. and Usman, A. (2022). The Economic Effects of Brexit: Evidence from the Stock Market. *Fiscal Studies*, 39(4), pp.581–623.

Chan, B.A. and Hughes, B.G. (2015). Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Trans Lung Cancer Res, 4(1), pp.36*

Cormie, P., Atkinson, M. and Bucci, L. (2018). Clinical Oncology Society of Australia position statement on exercise in cancer care. *Medical Journal of Australia*. 209(4), pp.184–187

Demark-Wahnefried, W., Schildkraut, J.M., Iselin, C.E., Conlisk, E., Kavee, A., Aldrich, T.E., Lengerich, E.J., Walther, P.J. and Paulson, D.F., (1998). Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North

UNDER PEER REVIEW

Carolina. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, *83*(2), pp.320-330.

Dhieb, D., Belguith, I., Capelli, L., Chiadini, E., Canale, M. and Bravaccini, S. (2019). *Analysis of genetic alterations in Tunisian patients with lung adenocarcinoma. Cells, 8, pp.514.*

Dietze, E.C., Sistrunk, C., Miranda-Carboni, G., O'regan, R. and Seewaldt, V.L., (2015). Triple-negative breast cancer in African-American women: disparities versus biology. *Nature Reviews Cancer*, *15*(4), pp.248-254.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C. and Rebelo, M. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. *International Journal of Cancer, 136, pp.359–386.*

Garg, A., Iyer, H. and Jindal, V. (2022). Prognostic factors for treatment response and survival outcomes after first-line management of stage 4 non-small cell lung cancer: A real-world Indian perspective. *Lung India, 39(2), pp. 102-109.*

Ginsburg, O., Bray, F., Coleman, M.P., Vanderpuye, V., Eniu, A., Kotha, S.R., Sarker, M., Huong, T.T., Allemani, C., Dvaladze, A. and Gralow, J., 2017. The global burden of women's cancers: a grand challenge in global health. *The Lancet*, *389*(10071), pp.847-860.

Gizaw, M., Addissie, A. and Getachew, S. (2017). "Cervical cancer patients presentation and survival in the only oncology referral hospital Ethiopia: a retrospective cohort study." *Infectious Agents and Cancer*, 12(1), pp.61–67.

Ingleby, F.C., Woods, L.M., Atherton, I.M., Baker, M., Elliss-Brookes, L. and Belot, A. (2022). An investigation of cancer survival inequalities associated with individual level socio-economic status, area-level deprivation, and contextual effects, in a cancer patient cohort in England and Wales. *BMC Public Health*, 10(2), pp.34-39.

Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D., (2011). Global cancer statistics. *CA: a cancer journal for clinicians*, *61*(2), pp.69-90.

Kenfield, S.A., Stampfer, M.J., Chan, J.M. and Giovannucci, E. (2011). Smoking and prostate cancer survival and recurrence. *Jama (2011) 305, pp. 2548–2555.*

UNDER PEER REVIEW

Lei, J., Ploner, A., Elfström, K.M., Wang, J., Roth, A. and Fang, F. (2020). HPV vaccination and the risk of invasive cervical cancer. *New England Medical Journal, 383, pp.1340–1348.*

Mahal, B.A., Butler, S. and Franco, I. (2019). "Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010–2015," *The Journal of the American Medical Association*, 321(7), pp.704–706.

Medimegh, .I, Troudi, W., Omrane, I., Ayari, H., Uhrhummer, N. and Majoul, H. (2015). *Consanguinity protecting effect against breast cancer among Tunisian women: analysis of brca1 haplotypes.* Asian Pacific Journal Cancer Prev *16:4051–4055.*

Miller, K.D., Siegel, R.L. and Lin, C.C. (2016). "Cancer treatment and survivorship statistics." *CA: A Cancer Journal for Clinicians*, 66(4), pp.271–289.

Okunade, K.S., (2020). Human papillomavirus and cervical cancer. *Journal of Obstetrics and Gynaecology*, *40*(5), pp.602-608.

Patra, S. and Panda, D. (2010). Cervical cancer screening in developing countries. *Indian Journal of Cancer*, 47, pp.344-345

Rawla, P., (2019). Epidemiology of prostate cancer. *World journal of oncology*, *10*(2), p.63.

Saxena, S., Rekhi, B., Bansal, A., Bagga, A. and Murthy, N.S., (2005). Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-A cross-sectional study. *World journal of surgical oncology*, *3*, pp.1-8.

Soneji, S., Tanner, N.T., Silvestri, G.A., Lathan, C.S. and Black, W. (2017). Racial and ethnic disparities in early-stage lung cancer survival. *Chest*. 52(3), pp.587-597.

Torre, L.A., Siegel, R.L. and Jemal, A., (2016). Lung cancer statistics. *Lung cancer and personalised medicine: current knowledge and therapies*, pp.1-19.

Torre, L.A., Siegel, R.L., Ward, E.M. and Jemal, A. (2016). Global cancer incidence and mortality rates and trends-an update. *Cancer Epidemiology Biomarkers Prev*.25, pp.16–27.

UNDER PEER REVIEW

Wassie, M. and Fentie, B. (2021). “Prevalence of late-stage presentation and associated factors of cervical cancer patients in Tikur Anbesa Specialized Hospital Ethiopia: institutional based cross-sectional study.” *Infectious Agents and Cancer*, 16(1), pp.30.

White, V., Bergin, R.J., and Thomas, R.J. (2020). The pathway to diagnosis and treatment for surgically managed lung cancer patients. *Fam Practices*, 37, pp.234–41.

UNDER PEER REVIEW